HIV: Complera Non-Inferior to Atripla - MedPage Today
HIV: Complera Non-Inferior to AtriplaMedPage TodayDURBAN, South Africa – A head-to-head comparison of two single-tablet combinations appears to position rilpivirine plus tenofovir and emtricitabine (Complera) as an option for treatment alongside standard-of-care efavirenz plus tenofovir and .
Atripla three times weekly maintains HIV viral suppression for 24 weeks - aidsmap
Atripla three times weekly maintains HIV viral suppression for 24 weeksaidsmapPeople with undetectable viral load who switched from taking the Atripla single-tablet regimen (efavirenz/tenofovir/emtricitabine) every day to just every other weekday were able to maintain viral suppression for six months, and longer follow-up is .
Gilead Sciences (GILD) Shares are Down -0.14% - Trade Calls
Bidness ETCGilead Sciences (GILD) Shares are Down -0.
Gilead 's two phase 3b studies evaluating Odefsey to treat HIV-1 ... - pharmabiz.com
Money NewsGilead 's two phase 3b studies evaluating Odefsey to treat HIV-1 .
Atripla removed from preferred drug list - Windy City Times
Windy City TimesAtripla removed from preferred drug listWindy City TimesAtripla was the only single-tablet regimen ( STR ) HIV medication covered under the Illinois Medicaid program's preferred drug list.